Anaesthetic implications of anticancer chemotherapy

European Journal of Anaesthesiology

Volumn 20, Issue 11, 2003, Pages 859-871

  Kvolik, Slavica ^a   Glavas Obrovac, L ^b   Sakic, K ^b   Margaretic, D ^b   Karner, I ^b  

^a UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^b University of Zagreb School of Medicine   (Croatia)

Author keywords

Anaesthetics, general; Antineoplastic agents; Antineoplastic combined chemotherapy protocols; Combined modality therapy, chemotherapy, adjuvant, neoadjuvant therapy; Drug interactions, drug antagonism, drug synergism; Radiotherapy, adjuvant

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANASTROZOLE; ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; AROMATASE INHIBITOR; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FLUTAMIDE; GEMCITABINE; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT; LOCAL ANESTHETIC AGENT; METHOTREXATE; MORPHINE; PACLITAXEL; SEROTONIN 3 ANTAGONIST; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ALOPECIA; ANIMAL MODEL; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD LEUKEMIA; COMA; CONGESTIVE HEART FAILURE; DERMATITIS; DIARRHEA; DRUG HYPERSENSITIVITY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GENERAL ANESTHESIA; GERM CELL TUMOR; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYDRONEPHROSIS; HYPOPROTEINEMIA; INTERSTITIAL PNEUMONIA; LEUKEMIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MELANOMA; MORTALITY; MOUTH CANCER; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PARALYSIS; PERIPHERAL NEUROPATHY; PREOPERATIVE EVALUATION; PROSTATE CANCER; RAT; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; URETER OBSTRUCTION; UTERUS CANCER; VAGINA BLEEDING; VOMITING;

ANESTHESIA; ANESTHETICS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS;

EID: 0242557590     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S026502150300139X     Document Type: Review

References (110)

1. Kiyomiya K, Matsuo S, Kurebe M. Differences in intracellular sites of action of adriamycin in neoplastic and normal differentiated cells. Cancer Chemother Pharmacol 2001; 47: 51-56.
2. Neuendank A, Hartmann R, Buhrer C, et al. Acute toxicity and effectiveness of idarubicin in childhood acute lymphoblastic leukemia. Eur J Haematol 1997; 58: 326-332.
3. Marruchella A, Franco C, Garavaldi G, Uccelli M, Bottrighi P. Bleomycin-induced upper lobe fibrosis: a case report. Tumorigenesis 2002; 88: 414-416.
4. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Trends in mortality from Hodgkin's disease in western and eastern Europe. Br J Cancer 2002; 87: 291-293.
5. Brenner H, Kaatsch P, Burkhardt-Hammer T, Harms DO, Schrappe M, Michaelis J. Long-term survival of children with leukemia achieved by the end of the second millennium. Cancer 2001; 92: 1977-1983.
6. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
7. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 98: 847-853.
8. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
9. Shapiro JD, Rothenberg ML, Sarosy GA, et al. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer 1998; 83: 1980-1988.
10. Crown JP. The platinum agents: a role in breast cancer treatment? Semin Oncol 2001; 28: 28-37.
11. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002; 20: 1361-1367.
12. Gibbs P, Anderson C, Pearlman N, et al. A phase 2 study of neoadjuvant biochemotherapy for stage 3 melanoma. Cancer 2002; 94: 470-476.
13. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88: 338-356.
14. Mannaerts GHH, Van Zundert AAJ, Meeusen VCH, et al. Anaesthesia for advanced rectal cancer patients treated with combined major resections and intraoperative radiotherapy: Eur J Anaesthesiol 2002; 19: 742-748.
15. Ridwelski K, Meyer F, Hribaschek A, Kasper U, Lippert H. Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurrence of peritoneal carcinomatosis. J Surg Oncol 2002; 79: 10-16.
16. Hayden BH, Murray TG, Scott IU, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol 2000; 118: 1549-1554.
17. McCune WJ, Vallance DK, Lynch III JP. Immunosuppressive drug therapy. Curr Opin Rheumatol 1994; 6: 262-272.
18. Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969-974.
19. Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schonlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001; 21: 128-133.
20. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360: 923-924.
21. Kanamori H, Tanaka M, Kawaguchi H, et al. Resolution of psoriasis following allogenic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol 2002; 71: 41-44.
22. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2002; 25: 913-927.
23. Fisher B, Gunduz N, Saffer EA. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989; 49: 2002-2004.
24. Von Minckwitz G, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999-2005.
25. De Mateis A, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-centre, phase 2 study, Cancer 2002; 94: 895-901.
26. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
27. Grau JJ, Domingo J, Blanch JL, et al. Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy: a phase 2 study. Oncology 2002; 63: 338-345.
28. Duffy SW, Nixon RM. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 2002; 86: 218-221.
29. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project b-14 randomised trial. J Natl Cancer Ins 2001; 93: 684-690.
30. Cummings FJ. Evolving uses of hormonal agents for breast cancer therapy. Clin Ther 2002; 24 (Suppl C): C3-C25.
31. Trunet PF, Bhatnagar AS, Chaudri HA, Hornberger U. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Acta Oncol 1996; 35: 15-18.
32. Calabresi P, Chabner BA. Chemotherapy of neoplastic diseases. Introduction. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. New York, USA: McGraw-Hill Inc, 2001: 1381-1388.
33. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
34. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 2001; 92: 146-152.
35. Ozols RF. Role of carboplatin in ovarian cancer. Current results and thoughts for the future. Acta Obstet Gynecol Scand 1992; 155 (Suppl): 75-77.
36. Stewart CF, Arbuck, SG, Fleming, RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther 1991; 50: 385-393.
37. Laine PO, Lindqvist JC, Pyrhonen SO, Teerenhovi LM, Syrjanen SM, Meurman JH. Lesions of the oral mucosa in lymphoma patients receiving cytostatic drugs. Eur J Cancer B Oral Oncol 1993; 29B: 291-294.
38. Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K. Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small lung cancer. J Clin Oncol 1996; 14: 1071-1076.
39. Souglakos J, Kotsakis A, Kouroussis C, et al. Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumours Cancer 2002; 95: 1326-1333.
40. Fukumi D, Uchikoba Y, Maeda M, Ogawa S. Longitudinal evaluation of anthracycline cardiotoxicity by signal-averaged electrocardiography in children with cancer. Pediatr Int 2002; 44: 134-140.
41. Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. New York, USA: McGraw-Hill Inc, 2001: 1389-1459.
42. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 2002; 20: 1677-1682.
43. May D, Wandl U, Becher R, Niederle N, Schmidt CG. Cardiac side-effects of 5-fluorouracil: Dtsch Med Wochenschr 1990; 115: 618-621.
44. Dimopoulou I, Galani H, Dafni U, Samakovli A, Roussos C, Dimopoulous M. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 2002; 94: 452-458.
45. Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel induced bilateral pneumonitis. Ann Pharmacother 1997; 31: 1471-1474.
46. Fujimori K, Yokojama A, Kurita Y, Uno K, Saijo N. Paclitaxel induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55: 340-344.
47. Agraharkar M, Nerenstone S, Palmisano J, Kaplan AA. Carboplatin-related hematuria and acute renal failure. Am J Kidney Dis 1998; 32: E5.
48. Hartmann JT, Fels LM, Franzke A, et al. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 2000; 20: 3767-3773.
49. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322-1329.
50. Van Outryve S, Schrijvers D, Van den Brande J, et al. Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med 2002; 60: 216-222.
51. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-176.
52. Rosenthal SA, Linstadt DE, Leibenhaut MH, et al. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996; 199: 451-455.
53. Kraus I, Vitezic D, Oguic R. Flutamide-induced acute hepatitis in advanced prostate cancer patients. Int J Clin Pharmacol Ther 2001; 39: 395-399.
54. Tran A, Housset C, Boboc B, Tourani JM, Carnot F, Berthelot P. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991; 12: 36-39.
55. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8: 1874-1879.
56. Fisher B, Keenan AM, Garra BS, et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 1989; 7: 1852-1862.
57. Chojnowski K, Wawrzyniak E, Trelinski J, Niewiarowska J, Cierniewski C. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma 1999; 36: 77-84.
58. Smorenburg SM, Hutten BA, Prins MH. Should patients with venous thromboembolism and cancer be treated differently? Haemostasis 1999; 29 (Suppl S1): 91-97.
59. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 1993; 4: 935-942.
60. Johnson PE, Buzdar A. Are differences in the available aromatase inhibitors and inactivators significant? Clin Cancer Res 2001; 7 (Suppl 12): 4360s-4368s.
61. Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Ther 2002; 24 (Suppl C): C26-C42.
62. Gutman H, Schachter J, Stopel E, Gutman R, Lahav J. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. Cancer 2002; 94: 780-785.
63. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207.
64. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486-2493.
65. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165-1170.
66. Hilkens PH, Van den Bent MJ. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 1997; 2: 350-361.
67. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999; 91: 1829-1846.
68. Saso R, Kulkarni S, Mitchell P, et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000; 83: 91-94.
69. Wilkinson G R. Pharmacokinetics. The dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. New York, USA: McGraw-Hill Inc, 2001: 3-29.
70. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449-459.
71. Glue P, Clement RP. Cytochrome P450 enzymes and drug metabolism: basic concepts and methods of assessment. Cell Mol Neurobiol 1999; 19: 309-323.
72. Bohnenstengel F, Friedel G, Ritter CA, et al. Variability of cyclophosphamide uptake into human bronchial carcinoma: consequences for local bioactivation. Cancer Chemother Pharmacol 2000; 45: 63-68.
73. Fitzsimmons SA, Workman P, Grever M, Paul K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996; 88: 259-269.
74. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002; 30: 438-445.
75. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19-38.
76. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99-114.
77. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in human. Cancer Res 1996; 56: 1296-1302.
78. Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001; 39: 517-528.
79. Kenna JG, Jones RM. The organ toxicities of inhaled anaesthetics. Anesth Analg 1995; 81: S51-S66.
80. Eger II EI, Laster MJ, Winegar R, Han C, Gong D. Compound A induces sister chromatid exchanges in Chinese hamster ovary cells. Anesthesiology 1997; 86: 918-922.
81. Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 2000; 9: 43-76.
82. Gorsky JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and claritromycin. Clin Pharmacol Ther 1998; 64: 133-143.
83. Bohrer H, Schmidt H, Bach A, et al. Inhibition of hepatic microsomal drug metabolism by atracurium administration in the rat. Pharmacol Toxicol 1993; 73: 137-141.
84. Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 2001; 18: 543-546.
85. Thorne AC, Orazem JP, Shah NK, et al. Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. J Cardiothorac Vasc Anesth 1993; 7: 307-311.
86. Ludwig Breast Cancer Study Group. Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet 1983; 2: 542-544.
87. Chlebowski RT, Block JB, Cundiff D, Dietrich MF. Doxorubicin cytotoxicity enhanced by local anesthetics in a human melanoma cell line. Cancer Treat Rep 1982; 66: 121-125.
88. Kennedy KA, Hait WN, Lazo JS. Chemical modulation of bleomycin induced toxicity. Int J Radiat Oncol Biol Phys 1986; 12: 1367-1370.
89. Friedrich P, Schmitz TP. Lidocaine-induced cell death in human model of neuronal apoptosis. Eur J Anaesthesiol 2002; 19: 564-570.
90. Ermens AA, Schoester M, Spijkers LJ, Lindemans J, Abels J. Toxicity of methotrexate in rats preexposed to nitrous oxide. Cancer Res 1989; 49: 6337-6341.
91. Koblin DD. Nitrous oxide: a cause of cancer or chemotherapeutic adjuvant? Semin Surg Oncol 1990; 6: 141-147.
92. Rosenow S, Kooistra KL, Powis G, Van Dyke RA. Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. Cancer Chemother Pharmacol 1986; 16: 35-42.
93. Rudnick S, Stevenson GW, Hall SC, Espinoza-Delgado I, Stevenson HC, Longo DL. Halothane potentiates the antitumor activity of gamma-interferon and mimics calmodulin-blocking agents. Anesthesiology 1991; 74: 115-119.
94. Thorne AC, Orazem JP, Shah NK, et al. Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. J Cardiothorac Vasc Anesth 1993; 7: 307-311.
95. 2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumour xenografts. Anesth Analg 1999; 88: 559-567.
96. Miccoli L, Poirson-Bichat F, Sureau F, et al. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 1998; 90: 1400-1406.
97. D'Mello D, Mehta D, Pereira J, Rao CV. A toxicity study of simultaneous administration of Tamoxifen and Diazepam to female Wistar rats. Exp Toxicol Pathol 1999; 51: 549-553.
98. Ingrassia III TS, Ryu JH, Trastek VF, Rosenow III EC. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc 1991; 66: 173-178.
99. Van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999; 15: 166-172.
100. Tsang RW, Solow HL, Ananthanarayan C, Haley S. Daily general anaesthesia for radiotherapy in unco-operative patients: ingredients for successful management. Clin Oncol 2001; 13: 416-421.
101. Borgeat A, Wilder-Smith OH, Wilder-Smith CH, Forni M, Suter PM. Propofol improves patient comfort during cisplatin chemotherapy. A pilot study. Oncology 1993; 50: 456-459.
102. Wilcock A, Twycross R. Midazolam for intractable hiccup. J Pain Symptom Manage 1996; 12: 59-61.
103. Arcioni R, della Rocca M, Romano S, Romano R, Pietropaoli P, Gasparetto A. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans. Anesth Analg 2002; 94: 1553-1557.
104. Dershwitz M, Di Biase PM, Rosow CE, Wilson RS, Sanderson PE, Joslyn AF. Ondansetron does not affect alfentanil-induced ventilatory depression or sedation. Anesthesiology 1992; 77: 447-452.
105. Lawlor PG. The panorama of opioid related cognitive dysfunction in patients with cancer. Cancer 2002; 94: 1836-1854.
106. Franciosi C, Bravo AF, Romano F, et al. Immunodeficiency in radically operable gastric cancer patients. Hepatogastroenterology 2002; 49: 857-859.
107. Kurtz A, Sessler D, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical wound infection and shortened hospitalisation. N Eng J Med 1996; 334: 1209-1215.
108. Frank SM, Fleischer LA, Breslow MJ, et al. Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomised clinical trial. JAMA 1997; 227: 1127-1134.
109. Bock M, Muller J, Bach A, Bohrer H, Martin E, Motsch J. Effects of preinduction and intraoperative warming during major laparotomy. Br J Anaesth 1998; 80: 159-163.
110. Ben-Eliyahu S, Shakhar G, Rosenne E, Levinson Y, Beilin B. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology 1999; 91: 732-740.